Last updated on October 2018

A Safety and Pharmacokinetics Study of Niraparib Plus an Androgen Receptor-Targeted Therapy in Men With Metastatic Castration-Resistant Prostate Cancer (BEDIVERE)


Brief description of study

The purpose of this study is to assess the safety and pharmacokinetics of niraparib when administered in combination with an androgen receptor (AR)-targeted therapy (apalutamide or abiraterone acetate plus prednisone) in adult men with metastatic castration resistant prostate cancer (mCRPC) who may or may not have deoxyribonucleic acid (DNA)-repair anomalies.

Clinical Study Identifier: NCT02924766

Contact Investigators or Research Sites near you

Start Over

Use link at the bottom ...

Cedars-Sinai Medical Center
West Hollywood, CA United States
  Connect »

Use link at the bottom ...

Norton Healthcare
Louisville, KY United States
  Connect »

Use link at the bottom ...

Oregon Health & Science University
Portland, OR United States
  Connect »

Use link at the bottom ...

Carolina Urologic Research Center
Myrtle Beach, SC United States
  Connect »

Use link at the bottom ...

British Columbia Cancer Agency (BCCA) - Vancouver Prostate Centre
Vancouver, BC Canada
  Connect »

Use link at the bottom ...

CHUM - Centre hospitalier universitaire de Montreal
Montreal, QC Canada
  Connect »